LONDON, United Kingdom, 10 January, 2013: Regent’s Park Heart Clinics (Regent’s Park), an independent company specialising in the provision of cardiology services, today announced it has been selected by a global pharmaceutical company with a market capitalisation of over £170 billion to provide clinical diagnostic services in 72 of its centres across the United Kingdom. The partnership has been operating since July 2012 across 10 sites and given its huge success will now be rolled out across 62 more centres in 2013.
Dr. Ohri, Chief Executive of Regent’s Park said: “Given the intense competition in this area of the pharmaceutical industry we are delighted to have passed, and in many areas exceeded, the rigorous quality and safety criteria they set before selecting a service partner.” He added: “The monitoring and clinical evaluation services we provide are led by our teams of cardiac physiologists and consultant cardiologists using a proprietary realtime tele-diagnostics solution we have developed in-house. This innovative method of data gathering and reporting means professional opinions on physiological changes to the heart and the potential cardiotoxicity of certain drugs are available instantaneously – rapid, high quality interpretation of clinical data in this type of environment is clearly crucial.”
More information on this exciting partnership will be released later this year.